Effectiveness of levocetirizine in treating allergic rhinitis while retaining work efficiency

IF 4.1 2区 医学 Q2 ALLERGY Allergy, Asthma & Immunology Research Pub Date : 2023-04-25 DOI:10.29328/journal.aaai.1001031
Y. Dabholkar, Tanush Shah, Roheet M Rathod, Akhila Paspulate, Chaitanya Veligandla Krishna, R. Rathod, Joshi Devesh Kumar, Bhavesh Kotak
{"title":"Effectiveness of levocetirizine in treating allergic rhinitis while retaining work efficiency","authors":"Y. Dabholkar, Tanush Shah, Roheet M Rathod, Akhila Paspulate, Chaitanya Veligandla Krishna, R. Rathod, Joshi Devesh Kumar, Bhavesh Kotak","doi":"10.29328/journal.aaai.1001031","DOIUrl":null,"url":null,"abstract":"The manifestation and severity of Allergic rhinitis symptoms show diurnal variation which negatively impacts the patient’s quality of life, day-to-day activities, and productivity at the workplace. The symptoms worsen at night or early morning and therefore administration of levocetirizine towards evening may be more acceptable. Consequently, the present study evaluated the effectiveness of evening Levocetirizine administration on 24-hour symptom control, Physical and mental health, and daytime somnolence in patients with allergic rhinitis the study was a prospective, open-labeled, single-arm, two-center, observational study among patients with allergic rhinitis. Levocetirizine was prescribed as 5 mg or 10 mg once a day evening oral dose for at least 7 days before sleep. The 24-hour total nasal symptom scores (TNSS) for self-reported signs and symptoms of allergic rhinitis were recorded. Additionally, study evaluations included the SF-12 scale (Quality of Life), Stanford Sleepiness Scale (degree of sleepiness), and work productivity and activity impairment (WPAI) questionnaires. These evaluations were performed at baseline (Day 0) and at scheduled intervals of Day 1 (24-hour), Day 3, and Day 7. Results demonstrated that evening administration of Levocetirizine facilitates 24-hour symptom control while having no significant effect on daytime somnolence, daily activities, and the work productivity of patients.","PeriodicalId":7547,"journal":{"name":"Allergy, Asthma & Immunology Research","volume":"16 1","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2023-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy, Asthma & Immunology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.29328/journal.aaai.1001031","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

The manifestation and severity of Allergic rhinitis symptoms show diurnal variation which negatively impacts the patient’s quality of life, day-to-day activities, and productivity at the workplace. The symptoms worsen at night or early morning and therefore administration of levocetirizine towards evening may be more acceptable. Consequently, the present study evaluated the effectiveness of evening Levocetirizine administration on 24-hour symptom control, Physical and mental health, and daytime somnolence in patients with allergic rhinitis the study was a prospective, open-labeled, single-arm, two-center, observational study among patients with allergic rhinitis. Levocetirizine was prescribed as 5 mg or 10 mg once a day evening oral dose for at least 7 days before sleep. The 24-hour total nasal symptom scores (TNSS) for self-reported signs and symptoms of allergic rhinitis were recorded. Additionally, study evaluations included the SF-12 scale (Quality of Life), Stanford Sleepiness Scale (degree of sleepiness), and work productivity and activity impairment (WPAI) questionnaires. These evaluations were performed at baseline (Day 0) and at scheduled intervals of Day 1 (24-hour), Day 3, and Day 7. Results demonstrated that evening administration of Levocetirizine facilitates 24-hour symptom control while having no significant effect on daytime somnolence, daily activities, and the work productivity of patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
左西替利嗪在保持工作效率的同时治疗变应性鼻炎的疗效
变应性鼻炎症状的表现和严重程度呈昼夜变化,对患者的生活质量、日常活动和工作效率产生负面影响。症状在夜间或清晨加重,因此在傍晚给药左西替利嗪可能更可接受。因此,本研究评估了夜间给药左西替利嗪对变应性鼻炎患者24小时症状控制、身心健康和白天嗜睡的有效性。该研究是一项前瞻性、开放标记、单臂、双中心、变应性鼻炎患者的观察性研究。左西替利嗪为5毫克或10毫克,每天一次,晚上口服,睡前至少7天。记录患者自我报告的变应性鼻炎症状和体征的24小时鼻症状总评分(TNSS)。此外,研究评估包括SF-12量表(生活质量)、斯坦福嗜睡量表(嗜睡程度)和工作效率和活动障碍(WPAI)问卷。这些评估在基线(第0天)和第1天(24小时)、第3天和第7天的预定间隔进行。结果表明,夜间给药左西替利嗪有助于24小时症状控制,而对患者白天嗜睡、日常活动和工作效率无明显影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.10
自引率
6.80%
发文量
53
审稿时长
>12 weeks
期刊介绍: The journal features cutting-edge original research, brief communications, and state-of-the-art reviews in the specialties of allergy, asthma, and immunology, including clinical and experimental studies and instructive case reports. Contemporary reviews summarize information on topics for researchers and physicians in the fields of allergy and immunology. As of January 2017, AAIR do not accept case reports. However, if it is a clinically important case, authors can submit it in the form of letter to the Editor. Editorials and letters to the Editor explore controversial issues and encourage further discussion among physicians dealing with allergy, immunology, pediatric respirology, and related medical fields. AAIR also features topics in practice and management and recent advances in equipment and techniques for clinicians concerned with clinical manifestations of allergies and pediatric respiratory diseases.
期刊最新文献
Involvement of the Constitutive Photomorphogenesis 9 Signalosome Subunit 5 With Programmed Cell Death Protein 1 Ligand in Asthma. Neutrophil Extracellular Traps as a Biomarker in Refractory Non-Type 2 CRSwNP. Oral Administration of Lactococcus lactis Expressing Mite and Cockroach Major Allergens Alleviates Progression of Atopic March in a Mouse Model. Skin Lipid Barrier: Structure, Function and Metabolism. Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1